3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
34
Paraganglioma
6
Meningioma
6
Gastro-enteropancreatic neuroendocrine tumor
6
Pheochromocytoma
5
Carcinoma, Neuroendocrine
4
Neuroblastoma
3
Carcinoid Tumor
3
Adenoma, Islet Cell
3
Medulloblastoma
2
Glioma
2
Glioblastoma
2
Ependymoma
2
Carcinoma, Merkel Cell
2
Carcinoma, Medullary
2
Somatostatinoma
1
Small Cell Lung Carcinoma
1
Serotonin Syndrome
1
Sarcoma, Synovial
1
Recurrence
1
Prostatic Neoplasms
1
Pituitary Neoplasms
1
Parathyroid Neoplasms
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Metastatic Digestive System Neuroendocrine Tumor G1
1
Hypertension
1
Extensive Stage Small Cell Lung Cancer
1
Interventions
Docetaxel
8
Filgrastim
5
Cisplatin
5
Radiotherapy
4
Etoposide
3
Erlotinib Hydrochloride
3
Cetuximab
3
Capecitabine
3
Bevacizumab
3
sargramostim
2
Peripheral Blood Stem Cell Transplantation
2
Paclitaxel
2
Gemcitabine
2
Cyclophosphamide
2
Carboplatin
2
Acupuncture Therapy
2
vandetanib
1
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
tanespimycin
1
pentetreotide
1
oncogene protein E7, Human papillomavirus type 16
1
olaparib
1
oblimersen
1
lutetium Lu 177 dotatate
1
etoposide phosphate
1
entinostat
1
enasidenib
1
cevimeline
1
apatinib
1
aldesleukin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Esthesioneuroblastoma, Olfactory
×
lutetium Lu 177 dotatate
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled